peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GHRH analog · 44 amino acids

Tesamorelin

/tes-a-MOR-e-lin/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

Egrifta WR

Daily subcutaneous injection

Reduction of excess abdominal fat in adults with HIV and lipodystrophy.

Find official label ↗
02

Egrifta SV

Daily subcutaneous injection

Same narrow indication; WR and SV are not substitutable.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Binds pituitary GHRH receptors and stimulates pulsatile growth hormone release, increasing downstream IGF-1.Mechanism source
Labeled-use boundary
Not indicated for weight-loss management; it has a weight-neutral effect and long-term cardiovascular safety has not been established.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Who should avoid it

  • Disruption of the hypothalamic-pituitary axis
  • Active malignancy
  • Pregnancy
  • Hypersensitivity to tesamorelin or mannitol
Contraindications

More common effects

  • Arthralgia
  • Injection-site reactions
  • Pain in extremity
  • Peripheral edema
  • Myalgia
Adverse reactions

Important serious risks

  • Elevated IGF-1
  • Fluid retention
  • Glucose intolerance or diabetes
  • Hypersensitivity
  • Malignancy considerations
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

A narrow, measurable indication

Pivotal trials measured visceral adipose tissue in adults with HIV lipodystrophy.

Supporting source
Evidence form
Randomized controlled trials
Keep in view
The evidence does not support general obesity treatment.
02

Endocrine monitoring matters

IGF-1 and glucose effects are central labeled monitoring concerns.

Supporting source
Evidence form
Trial and label evidence
Keep in view
Long-term cardiovascular safety remains unestablished.
03

Formulations are not substitutes

WR and SV differ in concentration, preparation, and injection volume.

Supporting source
Evidence form
Current labeling
Keep in view
Brand familiarity is not enough to choose instructions.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    Egrifta WR prescribing information

    Current DailyMed label for the WR formulation, including non-substitutability language.

    Open source ↗
  2. 02Literature index
    Every PubMed result for tesamorelin

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for tesamorelin

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    tesamorelin chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗